Cambridge Healthtech Institute’s 6th Annual

Liquid Biopsy and CTCs in Clinical Trials

Part of 16th Annual Biomarker World Congress

June 16, 2021

 

Liquid biopsy is a maturing technology for early detection of disease, patient stratification and therapy selection, monitoring response to therapy, and detecting disease recurrence. Cambridge Healthtech Institute’s 6th Annual Liquid Biopsy and CTCs in Clinical Trials conference will explore the latest technologies in detection and molecular characterization of CTCs, cell-free circulating tumor DNA (cfDNA) and circulating extracellular RNA, exosomes and microvesicles, as well as the applications of liquid biopsy in diagnostics and drug development.  

 

Coverage will include, but is not limited to:

 

  • Technology update in liquid biopsy detection and characterization
  • Applications of cell-free DNA and RNA as biomarkers in drug development
  • Exosomes and microvesicles as biomarkers
  • Liquid biopsy for immuno-oncology drug development
  • Liquid biopsy for companion diagnostics
  • Cancer screening and early detection

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is January 29, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:

Julia Boguslavsky

Executive Director, Conferences

Cambridge Healthtech Institute

Email: juliab@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-247-6286

Email: reymael@healthtech.com